News Desk — May 18, 2018 at 7:19 am — Updated: May 18, 2018 at 7:19 am

AstraZeneca hit by falling Crestor sales, higher costs


LONDON (Reuters) – Generic competition to cholesterol fighter Crestor and higher costs hit AstraZeneca in the first quarter, despite good sales of new drugs, but the group said on Friday it remained on track for a promised return to sales growth in 2018.

Leave A Comment Using Facebook (Website Comment Form Below)

Use the form below to post a comment via facebook

Leave a Reply

68 queries in 0.973 seconds.